This novel mechanism of GAS5 suppressing stomach carcinogenesis via the YBX1/p21 pathway serves as a potential target for the development of lncRNA-based therapeutics for the treatment of stomach cancer. This evidence concerns the gene CDKN1A and gastric neoplasm.